14 source-based articles maintained by the HealthRX.com Editorial Team.
Showing 14 of 14 clinical reviews.
Mounjaro has no FDA-approved heart-failure dose. Review the final SUMMIT trial in obesity-related HFpEF, what its results show, and why trial titration is not a personal dosing protocol.
A clinical evidence summary of tirzepatide (Mounjaro) for heart failure, including SURMOUNT-HFpEF trial data, mechanism of action, current FDA-approved indications, and what the research means for patients with HFpEF.
Tirzepatide (Mounjaro) is not FDA-approved for heart failure, but emerging trial data suggest cardiovascular benefits in patients with HFpEF and obesity. Here is what clinicians and patients need to know about off-label use, risks, and tradeoffs.
Can Mounjaro (tirzepatide) be used for heart failure? Review the clinical trial data, off-label status, monitoring requirements, and what cardiologists recommend for HFpEF patients.
Tirzepatide (Mounjaro) is prescribed off-label for PCOS. Review the dosing protocol, clinical evidence for insulin resistance and ovulation, FDA status, and what the research actually shows.
Tirzepatide (Mounjaro) is not FDA-approved for PCOS, but emerging trial data suggest meaningful improvements in ovulation, insulin resistance, and androgen levels. Here is what clinicians and patients should know about the risks and tradeoffs.
Tirzepatide (Mounjaro) is not FDA-approved for PCOS, but emerging clinical data suggest it may improve insulin resistance, androgen levels, and ovulation in women with polycystic ovary syndrome. Here is what the research says.
Tirzepatide (Mounjaro) is being studied as a treatment for obstructive sleep apnea. Learn what the clinical trials show, what monitoring is required, and how it compares to FDA-approved options.
Tirzepatide (Mounjaro) is not FDA-approved for sleep apnea, but clinical trial data from SURMOUNT-OSA show significant AHI reductions. Here's what the evidence actually says about off-label use, risks, and who might benefit.
Tirzepatide (Mounjaro) is being used off-label for obstructive sleep apnea. Review the SURMOUNT-OSA trial data, dosing protocols, AHI reductions, and what clinicians should know before prescribing.
Tirzepatide (Mounjaro) is not FDA-approved for sleep apnea, but clinical trial data from SURMOUNT-OSA suggest meaningful reductions in AHI. Here is what the research says about off-label use.
Mounjaro (tirzepatide) is FDA-approved for type 2 diabetes, but physicians prescribe it off-label for weight loss. Learn what the SURMOUNT trials showed, how dosing works, and what to expect.
Tirzepatide (Mounjaro) is FDA-approved for type 2 diabetes but widely prescribed off-label for weight loss. Learn what the evidence shows, how it compares to Zepbound, and what monitoring your prescriber should order.
A clinical evidence summary of tirzepatide (Mounjaro) used off-label for weight loss, including trial data from SURMOUNT and SURPASS, dosing, safety, and how it compares to semaglutide.